Menu

Relieving Congestion in Acute Heart Failure (AHF) Patients.

ACUTE HEART FAILURE (AHF)

1M

HOSPITALIZED
ANNUALLY IN THE US

15-20%

SUFFER DELAYED OR POOR RESPONSE TO THERAPY

1in4

READMITTED
WITHIN 30 DAYS

AHF Background

Heart failure (HF) is a chronic, progressive disease in which the heart is unable to pump enough oxygen-rich blood to the body. Acute HF is the sudden worsening of this condition, mostly due to fluid congestion. Increase in blood volume elevates vascular pressure and affects the kidneys’ ability to exert urine and sodium, causing build-up in the extremities (edema), lungs (dyspnea), and other internal organs.

The key treatment is diuretic therapy, aimed at increasing the patient’s urine and sodium output.

Poor or delayed response to diuretics leads to increased mortality, longer hospitalization, and higher 30-day re-admission rates. This direct financial impact is not reimbursed to the hospitals, with potential added risk from The Affordable Care Act penalties.

Relieves congestion, restores organ function, enhances diuretic efficiency

The Doraya is designed to improve the efficacy of diuretic therapy in patients with acute heart failure (AHF). A manageable flow-reducing Central Venus Catheter, Doraya is deployed in the infrarenal IVC for up to 12 hours, helping cardiologists to temporarily manage venous hemodynamics, central venous pressure, renal afterload, and venous returns. Data from the Doraya First in Human feasibility study was presented at THT 2022 and featured in the March 2022 release of the Journal of the American College of Cardiology: Basic to Translational Science, demonstrating promising results. 
To see the full research letter [Download PDF].

The potential benefits of interventional decongestion

Improved diuretic
efficacy and urine output

Improved clinical signs
and symptoms
(edema, ascites, dyspnea)

Reduced length of
hospital stay

Reduced 30-day
readmissions

,,

We believe that the Doraya catheter may represent a promising effective treatment option for patients with acute heart failure and diuretic resistance. The elegance of this approach is that it addresses the local mechanism for diuretic resistance rather than apply the brute force of systemic drugs or dialysis.
Dr. Eugene S. Chung, MD, an Advanced Heart Failure cardiologist at The Christ Hospital in Cincinnati, OH
Despite the patient’s poor response to several days of aggressive standard therapy, the Doraya catheter increased aquaretic and natriuretic urine output, with significant reduction in both abdominal tension and weight at 48 hours.
Dr. Robert Zymliński, University Hospital, Wrocław, Poland
Based on this early experience, treatment with the Doraya catheter appears to be safe and helpful in overcoming diuretic resistance in AHF patients… offering the simultaneous targeting of both cardiac and renal hemodynamics.
Dr. Riet Dierckx, OLV, Aalst, Belgium
Regardless of reimbursement changes or country-specific idiosyncrasies, effective and durable decongestion will always be at the heart of profitable HF treatment.
Prof. Ulrich P. Jorde, MD, Montefiore Medical Center, New York, US

ABOUT US

Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. We believe that by using Doraya, cardiologists can enhance patient response to diuretic therapy, thereby rapidly alleviate signs and symptoms of congestion, improving patient outcomes and significantly reducing the financial burden of readmission. Revamp has a seasoned team of professionals with a proven track record in leading multiple med-tech startups.

OUR TEAM

Mike Favet

CEO

holds a Bachelor of Science in Mechanical Engineering from the University of Illinois and a Master of Business Administration degree from the Carlson School of Management at the University of Minnesota. He has more than 20 years of executive level experience successfully building, growing, and leading medical technology companies. He most recently worked as the CEO of NeuroPace where he led a significant commercial expansion and took the company public in 2021. Prior to NeuroPace, Mr. Favet served as Managing Director for KCK Medtech, a leading investment firm in medical technologies. He also held senior management positions at a variety of medical technology companies, including Advanced Cardiac Therapeutics, Sonitus Medical, Boston Scientific and Guidant. 

Yael Shohat

COO

holds a Master’s degree in biomedical engineering from the Technion University. She has vast experience in management of project timelines and budget; transferring the projects from development to production; preparation and execution of V&V, matrix management of project engineers. Yael has over a decade of R&D experience as a project manager in the development of the most challenging projects in the cardiac area. She has worked for innovative cardio related companies such as: CorAssist, V-Wave and EndoCross.

Sahar Boostenay

Clinical Director

holds a BSc in Medical Sciences from Tel-Aviv University. Sahar has over 6 years of experience in the clinical \ RA field with primary expertise in cardiovascular devices and structural heart.

Offer Razi

Senior Director of Operations and Engineering

holds a double BSc in Mechanical Engineering and Material Science from Ben-Gurion University. Offer has 4 years of experience in R&D of minimal invasive devices, participating and managing  projects from concept to clinical study, with full hand-on approach. Offer has previously worked at Asymmetric Medical.

Lihu Avitov

Co-founder, Board Member

holds a bachelor’s degree in Economics & Management and master’s degree in Industrial Engineering. For the last 20 years he has been involved in the medical device and investments industries. In his former position as CEO of Angioslide, a cardiovascular company with CE & FDA marketing approvals, he managed over 40 employees in Israel, Germany and US. Angioslide delivered thousands of catheters to global markets, and had commercial partners in US, EU, China and India. Additional positions included EVP and XT Ventures, CEO of Naiot Accelerator and a board member at YEDA (Weitzman Institute TT company) . In addition to his role as Revamp CEO, Lihu provides consulting service to Agate VC.

Rafi Benary

CTO, Co-founder

holds a Masters’ degree from the New York University in Material Science and a Mechanical Engineering. He is an entrepreneur of 4 start-up companies, bringing them from inception to clinical stage through effective planning and execution. Rafi has more than 20 years of experience in the medical device field. His former positions: Co-founder at Ventor Technologies and Pi-Cardia, founding CEO and CTO at EndoSpan.  Ventor, developing an innovative cardiac valve catheter, was sold to Medtronic in 2013, for $300M. Both Pi-Cardia and EndoSpan have partnered with strategic commercial partners prior to initiating sales.

CONTACT US

Revamp Medical Ltd. 5 Mefi, Netania, Israel, 4250489

T: +972-73-3819227 | info@revampmedical.com

This project has received funding from the European Union’s Horizon 2020 SME Instrument program under grant agreement nr 855362.

Privacy Policy

Terms of Use